The financials
Dianthus Therapeutics, Inc. by the numbers
For the full year FY2025, revenue was $2.0M (−67% year on year) and net income −$162M. Its largest product in 2024-Q3 was License at $2.2M, 50.3% of the disclosed total, just ahead of License at 49.7%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | n/a | $193K | n/a |
| Operating income | −$61M | −$35M | n/a |
| Net income | −$50M | −$32M | n/a |
| Diluted EPS | −$0.90 | −$0.88 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License | $2.2M | 50% |
| License | $2.2M | 50% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $761.0K (+64%)
License grew +294% year on year
Segment Latestquarter on quarteryear on year
- License$761.0K$761.0KQoQ +64%year on year +294%+64%+294%
- Royalty--QoQ -year on year ---